Facts & Figures
-
1.9 million
New Incidents of Colon Cancer**Source: GLOBOCAN 2020
-
51 million
Colonoscopies Performed
Worldwide**Numbers of the US, Canada, Poland, South Korea, Australia, India, and Russia: As of 2022 Japan: As of 2020 China, Germany, France, Italy, Spain, the UK: As of 2019
-
100
Diseases or Conditions TreatedAt Olympus we have versatile medical devices
with the ability to treat approximately
100* diseases or conditions*As of March 2023
-
TOP 3
Cancers TreatedOlympus provides products/solutions for lung, colorectum and stomach
- Three cancers from the top 5* highest incidence of cancers
*Top 3 highest incidence of cancers excluding breast and prostate cancer, as of March 2022.
Source: GLOBOCAN 2020 -
32,805
Employees Worldwide*1*1: As of March 2023, Including discontinued operation 4,124
38
Countries or Regions*2*2: As of March 2023
-
¥881.9 bn
Total Medical
Revenue FY2023*Medical Business occupies
the largest part of our revenue*Figures are fiscal year revenues as of March 2023
-
70%
Global Market Share*Olympus is the leader in
gastrointestinal endoscopic equipment*As of Oct 2022
-
291
AwardsSince 1966, Olympus has been consistently
honored with national and international design
awards for its innovative product designs.**As of March 2023
-
14,000
Patentsacross our product portfolio*
*As of March 2023
-
CO2“0”
Net zero CO2 emissions by 2030We set as a target of achieving net zero CO2 emissions by 2030 from our site operations
-
TOP 100
Global InnovatorSince 2012 to 2020, and in 2022 and
2023, Olympus has been awarded
as one of the top 100 most
innovative companies in the world.
https://clarivate.com/top-100-innovators/